{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-088792","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2025-09-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.655554+00:00","generated_at":"2026-05-17T06:19:25.861196+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Nektar Phase 2b rezpegaldesleukin meets primary endpoint; EASI-75 66% vs 34% placebo at week 16","bullets":["All three rezpegaldesleukin dose arms met primary endpoint of mean % EASI improvement at week 16 (p<0.001 vs placebo).","High dose (24 µg/kg q2w) achieved statistical significance on EASI-75 (66% vs 34%), vIGA-AD 0/1 (19% vs 8%), and Itch NRS (42% vs 16%) at week 16.","Placebo crossover to high dose showed deepening response: EASI-75 62% and vIGA-AD 0/1 38% at week 24.","Safety consistent with prior data; most common AE mild injection site reactions; one death in escape arm assessed unrelated.","Next milestones: maintenance data Q1 2026; alopecia areata data Dec 2025; Phase 3 planning underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-088792","json":"https://secwatch.observer/filing/0001213900-25-088792.json","markdown":"https://secwatch.observer/filing/0001213900-25-088792.md","text":"https://secwatch.observer/filing/0001213900-25-088792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390025088792/0001213900-25-088792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390025088792/ea0257842-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:19:25.861196+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}